
News|Articles|December 3, 2025
Unlocking Speed and Scalability in Biologics: GPEx® Lightning Executive Overview
Author(s)Catalent
Discover how Catalent’s GPEx® Lightning platform revolutionizes cell line development for complex biologics. This executive summary highlights how the platform enables rapid, high-titer expression of multispecific antibodies and other challenging proteins—accelerating timelines, improving production efficiency, and supporting commercial-scale manufacturing. Learn how tunable expression and digital control empower your team to overcome development bottlenecks and drive innovation in next-generation biologics.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
FDA Approval of Cytokinetics’ Myqorzo Reflects Specialty Cardio Drug Trend
2
How the Wegovy Pill Approval Reshapes Solid Dosage Manufacturing Strategy
3
Innovation and Market Exclusivity in the EU
4
Orchestrating the Pharmaceutical Future: Living Decision Engines and AI Integration
5